Crohn’s Disease: Pipeline

Crohn’s Disease: Pipeline

  • December 2017 •
  • 60 pages •
  • Report ID: 5336395 •
  • Format: PDF
In-depth analysis of pipeline products for Crohn’s disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including new clinical data and an evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Competition in the Crohn’s disease market is set to intensify as novel biologics and small molecule drugs gain regulatory approval.

The availability of anti-tumor necrosis factor (TNF) biosimilars has increased the barrier for entry into early lines of therapy. Emerging agents will have to demonstrate superior efficacy or safety to the leading anti-TNFs Remicade or Humira, and/or launch at a lower cost in order to gain reimbursement in the TNF inhibitor-naïve setting.

Novel stem cell therapy Cx601 has the potential to meet a key unmet need in the treatment of fistulizing Crohn’s disease; however, it will face several barriers upon launch.

Datamonitor Healthcare has analyzed the Crohn’s disease pipeline, validating pipeline candidates against a variety of sources. Novel therapies are assessed against marketed products, considering their clinical and commercial attributes.